Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients

Table 1

Characteristics of the IBD cohort.

	Ulcerative colitis or Crohn’s disease n (%)
Total number	1091 (100)
Patients 18 to 49 years	767 (70.3)
Patients older than 49 years	324 (29.7)
Female	599 (54.9)
No immunotherapies	249 (22.8)
Steroids only	8 (0.7)
TNF-alpha blockers: infliximab, adalimumab, golimumab	475 (43.5)
Infliximab	370 (33.9)
Adalimumab	95 (8.7)
Golimumab	9 (0.8)
IL 13/23 antibody: ustekinumab	154 (14.1)
Anti-integrin: vedolizumab	146 (13.4)
Immunotherapy combinations	45 (4.1)
Others (tofacitinib, purine analogues, methotrexate)	14 (1.3)